Marion Anliker-Ort (Marion Ort)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Placebo Controlled

Coronary Artery

Top Venues

Journal of clinical pharmacology

Clinical drug investigation

Basic & clinical pharmacology & toxicology

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Marion Anliker-Ort, Frédérique Rodieux, Victoria C Ziesenitz, Andrew Atkinson, Julia A Bielicki, Thomas O Erb, Nicolas Gürtler, Stefan Holland-Cunz, Urs Duthaler, Deborah Rudin, Manuel Haschke, John van den Anker, Marc Pfister, Verena Gotta
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study. Journal of clinical pharmacology 64 (7) (2024)
Priska Kaufmann, Clemens Muehlan, Marion Anliker-Ort, Giancarlo Sabattini, Nicholas Siebers, Jasper Dingemanse
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women. Journal of clinical pharmacology (2024)
Marion Anliker-Ort, Frédérique Rodieux, Victoria C Ziesenitz, Andrew Atkinson, Julia A Bielicki, Thomas O Erb, Nicolas Gürtler, Stefan Holland-Cunz, Urs Duthaler, Deborah Rudin, Manuel Haschke, John van den Anker, Marc Pfister, Verena Gotta
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study. Journal of clinical pharmacology (2024)
Marion Anliker-Ort, Frédérique Rodieux, Victoria C Ziesenitz, Andrew Atkinson, Julia A Bielicki, Thomas O Erb, Nicolas Gürtler, Stefan Holland-Cunz, Urs Duthaler, Deborah Rudin, Manuel Haschke, John van den Anker, Marc Pfister, Verena Gotta
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study. Journal of clinical pharmacology 64 (7) (2024)
Marion Anliker-Ort, Jasper Dingemanse, Luboš Janů, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Clinical drug investigation (2023)
Marion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, Marc Pfister, John van den Anker, Jasper Dingemanse, Priska Kaufmann
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist. Pharmacology research & perspectives 11 (4) (2023)
Marion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye, Luboš Janů, John van den Anker, Benjamin Berger, Priska Kaufmann
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor antagonist ACT-1014-6470 in vitro and in vivo. Clinical and translational science (2023)
Marion Anliker-Ort, Jasper Dingemanse, Chih-Hsuan Hsin, Muriel Richard, Eva Huehn, Giancarlo Sabattini, Jeroen van de Wetering, Rüdiger Kornberger, John van den Anker, Priska Kaufmann
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic & clinical pharmacology & toxicology 131 (2) (2022)
Marion Anliker-Ort, Jasper Dingemanse, Hervé Farine, Peter M A Groenen, Rüdiger Kornberger, John van den Anker, Priska Kaufmann
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement. British journal of clinical pharmacology (2022)
Muriel Richard, Priska Kaufmann, Marion Anliker-Ort, Rüdiger Kornberger, Jasper Dingemanse
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. CNS drugs 34 (3) (2021)